Dissecting Ongoing Research With Oncolytic Viruses in Melanoma

Bartosz Chmielowski, MD, PhD, discusses the rationale for investigating oncolytic viruses in melanoma.

Elizabeth Buchbinder, MD, discusses the implications of the FDA's decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.

Bently P. Doonan, MD, discusses treatment strategies for patients with advanced melanoma who have progressed on checkpoint inhibitors.

Bently P. Doonan, MD, discusses the utility of oncolytic viruses and the need for novel treatments after checkpoint inhibitors in advanced melanoma.